Literature DB >> 22897747

Pharmacological characterization of designer cathinones in vitro.

L D Simmler1, T A Buser, M Donzelli, Y Schramm, L-H Dieu, J Huwyler, S Chaboz, M C Hoener, M E Liechti.   

Abstract

BACKGROUND AND
PURPOSE: Designer β-keto amphetamines (e.g. cathinones, 'bath salts' and 'research chemicals') have become popular recreational drugs, but their pharmacology is poorly characterized. EXPERIMENTAL APPROACH: We determined the potencies of cathinones to inhibit DA, NA and 5-HT transport into transporter-transfected HEK 293 cells, DA and 5-HT efflux from monoamine-preloaded cells, and monoamine receptor binding affinity. KEY
RESULTS: Mephedrone, methylone, ethylone, butylone and naphyrone acted as non-selective monoamine uptake inhibitors, similar to cocaine. Mephedrone, methylone, ethylone and butylone also induced the release of 5-HT, similar to 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and other entactogens. Cathinone, methcathinone and flephedrone, similar to amphetamine and methamphetamine, acted as preferential DA and NA uptake inhibitors and induced the release of DA. Pyrovalerone and 3,4-methylenedioxypyrovalerone (MDPV) were highly potent and selective DA and NA transporter inhibitors but unlike amphetamines did not evoke the release of monoamines. The non-β-keto amphetamines are trace amine-associated receptor 1 ligands, whereas the cathinones are not. All the cathinones showed high blood-brain barrier permeability in an in vitro model; mephedrone and MDPV exhibited particularly high permeability. CONCLUSIONS AND IMPLICATIONS: Cathinones have considerable pharmacological differences that form the basis of their suggested classification into three groups. The predominant action of all cathinones on the DA transporter is probably associated with a considerable risk of addiction.
© 2012 The Authors. British Journal of Pharmacology © 2012 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22897747      PMCID: PMC3572571          DOI: 10.1111/j.1476-5381.2012.02145.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  56 in total

1.  In vitro model for evaluating drug transport across the blood-brain barrier.

Authors: 
Journal:  Adv Drug Deliv Rev       Date:  1999-04-05       Impact factor: 15.470

2.  Guide to Receptors and Channels (GRAC), 5th edition.

Authors:  Stephen P H Alexander; Alistair Mathie; John A Peters
Journal:  Br J Pharmacol       Date:  2011-11       Impact factor: 8.739

Review 3.  3,4-methylenedioxypyrovalerone (MDPV): chemistry, pharmacology and toxicology of a new designer drug of abuse marketed online.

Authors:  M Coppola; R Mondola
Journal:  Toxicol Lett       Date:  2011-10-08       Impact factor: 4.372

4.  Mephedrone, compared with MDMA (ecstasy) and amphetamine, rapidly increases both dopamine and 5-HT levels in nucleus accumbens of awake rats.

Authors:  J Kehr; F Ichinose; S Yoshitake; M Goiny; T Sievertsson; F Nyberg; T Yoshitake
Journal:  Br J Pharmacol       Date:  2011-12       Impact factor: 8.739

5.  Sympathomimetic toxicity in a case of analytically confirmed recreational use of naphyrone (naphthylpyrovalerone).

Authors:  Adrian Derungs; Simeon Schietzel; Markus R Meyer; Hans H Maurer; Stephan Krähenbühl; Matthias E Liechti
Journal:  Clin Toxicol (Phila)       Date:  2011-07-08       Impact factor: 4.467

6.  Comparative neuropharmacology of three psychostimulant cathinone derivatives: butylone, mephedrone and methylone.

Authors:  Raul López-Arnau; Jose Martínez-Clemente; David Pubill; Elena Escubedo; Jorge Camarasa
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

7.  Psychological and physiological effects of MDMA ("Ecstasy") after pretreatment with the 5-HT(2) antagonist ketanserin in healthy humans.

Authors:  M E Liechti; M R Saur; A Gamma; D Hell; F X Vollenweider
Journal:  Neuropsychopharmacology       Date:  2000-10       Impact factor: 7.853

8.  1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors.

Authors:  Peter C Meltzer; David Butler; Jeffrey R Deschamps; Bertha K Madras
Journal:  J Med Chem       Date:  2006-02-23       Impact factor: 7.446

9.  Stereochemical effects of 3,4-methylenedioxymethamphetamine (MDMA) and related amphetamine derivatives on inhibition of uptake of [3H]monoamines into synaptosomes from different regions of rat brain.

Authors:  T D Steele; D E Nichols; G K Yim
Journal:  Biochem Pharmacol       Date:  1987-07-15       Impact factor: 5.858

10.  Duloxetine inhibits effects of MDMA ("ecstasy") in vitro and in humans in a randomized placebo-controlled laboratory study.

Authors:  Cédric M Hysek; Linda D Simmler; Valentina G Nicola; Nerina Vischer; Massimiliano Donzelli; Stephan Krähenbühl; Eric Grouzmann; Jörg Huwyler; Marius C Hoener; Matthias E Liechti
Journal:  PLoS One       Date:  2012-05-04       Impact factor: 3.240

View more
  229 in total

1.  Exposure of adolescent mice to 3,4-methylenedioxypyrovalerone increases the psychostimulant, rewarding and reinforcing effects of cocaine in adulthood.

Authors:  R López-Arnau; M A Luján; L Duart-Castells; D Pubill; J Camarasa; O Valverde; E Escubedo
Journal:  Br J Pharmacol       Date:  2017-04-06       Impact factor: 8.739

2.  Intravenous self-administration of entactogen-class stimulants in male rats.

Authors:  Sophia A Vandewater; Kevin M Creehan; Michael A Taffe
Journal:  Neuropharmacology       Date:  2015-08-21       Impact factor: 5.250

3.  Effects of orally self-administered bath salt constituent 3,4-methylenedioxypyrovalerone (MDPV) in mice.

Authors:  Brenda M Gannon; Lauren N Russell; Meet S Modi; Kenner C Rice; William E Fantegrossi
Journal:  Drug Alcohol Depend       Date:  2017-08-04       Impact factor: 4.492

4.  Chemokines and 'bath salts': CXCR4 receptor antagonist reduces rewarding and locomotor-stimulant effects of the designer cathinone MDPV in rats.

Authors:  Chicora F Oliver; Steven J Simmons; Sunil U Nayak; Garry R Smith; Allen B Reitz; Scott M Rawls
Journal:  Drug Alcohol Depend       Date:  2018-03-10       Impact factor: 4.492

5.  Synthetic psychoactive cathinones: hypothermia and reduced lethality compared to methamphetamine and methylenedioxymethamphetamine.

Authors:  Dawn E Muskiewicz; Federico Resendiz-Gutierrez; Omar Issa; F Scott Hall
Journal:  Pharmacol Biochem Behav       Date:  2020-02-12       Impact factor: 3.533

6.  Pharmacological profile of novel psychoactive benzofurans.

Authors:  Anna Rickli; Simone Kopf; Marius C Hoener; Matthias E Liechti
Journal:  Br J Pharmacol       Date:  2015-04-24       Impact factor: 8.739

Review 7.  Neurotoxicology of Synthetic Cathinone Analogs.

Authors:  Mariana Angoa-Pérez; John H Anneken; Donald M Kuhn
Journal:  Curr Top Behav Neurosci       Date:  2017

8.  Effects of the second-generation "bath salt" cathinone alpha-pyrrolidinopropiophenone (α-PPP) on behavior and monoamine neurochemistry in male mice.

Authors:  Azizi Ray; Neha Milind Chitre; Cedrick Maceo Daphney; Bruce E Blough; Clinton E Canal; Kevin Sean Murnane
Journal:  Psychopharmacology (Berl)       Date:  2018-10-01       Impact factor: 4.530

9.  Effects of 3,4-methylenedioxypyrovalerone (MDPV) pre-exposure on the aversive effects of MDPV, cocaine and lithium chloride: Implications for abuse vulnerability.

Authors:  Claudia J Woloshchuk; Katharine H Nelson; Kenner C Rice; Anthony L Riley
Journal:  Drug Alcohol Depend       Date:  2016-08-07       Impact factor: 4.492

10.  Synthesis, characterization and monoamine transporter activity of the new psychoactive substance mexedrone and its N-methoxy positional isomer, N-methoxymephedrone.

Authors:  Gavin McLaughlin; Noreen Morris; Pierce V Kavanagh; John D Power; Geraldine Dowling; Brendan Twamley; John O'Brien; Brian Talbot; Donna Walther; John S Partilla; Michael H Baumann; Simon D Brandt
Journal:  Drug Test Anal       Date:  2016-09-21       Impact factor: 3.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.